Blocking Neuropilin-2 Function Inhibits Tumor Cell Metastasis

Cancer Cell

Volumn 13, Issue 4, 2008, Pages 331-342

  Caunt, Maresa ^a   Mak, Judy ^a   Liang, Wei Ching ^a   Stawicki, Scott ^a   Pan, Qi ^a   Tong, Raymond K ^a   Kowalski, Joe ^a   Ho, Calvin ^a   Reslan, Hani Bou ^a   Ross, Jed ^a   Berry, Leanne ^a   Kasman, Ian ^a   Zlot, Constance ^a   Cheng, Zhiyong ^a   Le Couter, Jennifer ^a   Filvaroff, Ellen H ^a   Plowman, Greg ^a   Peale, Franklin ^a   French, Dorothy ^a   Carano, Richard ^a   Koch, Alexander W ^a   Wu, Yan ^a   Watts, Ryan J ^a   Tessier Lavigne, Marc ^a   Bagri, Anil ^a   more..

^a GENENTECH INC   (United States)

Author keywords

CELLCYCLE

Indexed keywords

MONOCLONAL ANTIBODY; NEUROPILIN 2; NEUROPILIN 2 ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LYMPH VESSEL; LYMPHANGIOGENESIS; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SENTINEL LYMPH NODE; TUMOR CELL;

MUS;

EID: 41249088330     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.01.029     Document Type: Article

References (39)

1. Achen M.G., and Stacker S.A. Tumor lymphangiogenesis and metastatic spread-New players begin to emerge. Int. J. Cancer 119 (2006) 1755-1760
2. Achen M.G., Mann G.B., and Stacker S.A. Targeting lymphangiogenesis to prevent tumour metastasis. Br. J. Cancer 94 (2006) 1355-1360
3. Alitalo K., and Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1 (2002) 219-227
4. Aslakson C.J., and Miller F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52 (1992) 1399-1405
5. Bernstein J.J., and Woodard C.A. Glioblastoma cells do not intravasate into blood vessels. Neurosurgery 36 (1995) 124-132
6. Brkovic A., and Sirois M.G. Vascular permeability induced by VEGF family members in vivo: Role of endogenous PAF and NO synthesis. J. Cell. Biochem. 100 (2007) 727-737
7. Cai H., and Reed R.R. Cloning and characterization of neuropilin-1-interacting protein: A PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J. Neurosci. 19 (1999) 6519-6527
8. Cao R., Eriksson A., Kubo H., Alitalo K., Cao Y., and Thyberg J. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ. Res. 94 (2004) 664-670
9. Carmeliet P., and Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature 436 (2005) 193-200
10. Chen H., Chedotal A., He Z., Goodman C.S., and Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 19 (1997) 547-559
11. Chen H., He Z., Bagri A., and Tessier-Lavigne M. Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins. Neuron 21 (1998) 1283-1290
12. Chen Z., Varney M.L., Backora M.W., Cowan K., Solheim J.C., Talmadge J.E., and Singh R.K. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 65 (2005) 9004-9011
13. El Mourabit H., Poinat P., Koster J., Sondermann H., Wixler V., Wegener E., Laplantine E., Geerts D., Georges-Labouesse E., Sonnenberg A., et al. The PDZ domain of TIP-2/GIPC interacts with the C-terminus of the integrin α5 and α6 subunits. Matrix Biol. 21 (2002) 207-214
14. Favier B., Alam A., Barron P., Bonnin J., Laboudie P., Fons P., Mandron M., Herault J.P., Neufeld G., Savi P., et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 108 (2006) 1243-1250
15. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
16. Gluzman-Poltorak Z., Cohen T., Herzog Y., and Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165. J. Biol. Chem. 275 (2000) 29922
17. Gupta G.P., and Massague J. Cancer metastasis: Building a framework. Cell 127 (2006) 679-695
18. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., and Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94 (2002) 819-825
19. Hoshida T., Isaka N., Hagendoorn J., di Tomaso E., Chen Y.-L., Pytowski B., Fukumura D., Padera T.P., and Jain R.K. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-c increases metastasis by increasing delivery of cancer cells to lymph nodes: Therapeutic implications. Cancer Res. 66 (2006) 8065-8075
20. Isaka N., Padera T., Fukumura D., and Jain R.K. Peritumor lymphatics induced by VEGF-C exhibit abnormal function. Cancer Res. 64 (2004) 4400-4404
21. Ji R.C., and Kato S. Lymphatic network and lymphangiogenesis in the gastric wall. J. Histochem. Cytochem. 51 (2003) 331-338
22. Joukov V., Sorsa T., Kumar V., Jeltsch M., Claesson-Welsh L., Cao Y., Saksela O., Kalkkinen N., and Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16 (1997) 3898-3911
23. Joukov V., Kumar V., Sorsa T., Arighi E., Weich H., Saksela O., and Alitalo K. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J. Biol. Chem. 273 (1998) 6599-6602
24. Karpanen T., Heckman C.A., Keskitalo S., Jeltsch M., Ollila H., Neufeld G., Tamagnone L., and Alitalo K. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 20 (2006) 1462-1472
25. Krishnan J., Kirkin V., Steffen A., Hegen M., Weih D., Tomarev S., Wilting J., and Sleeman J.P. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 63 (2003) 713-722
26. Kubo H., Cao R., Brakenhielm E., Makinen T., Cao Y., and Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc. Natl. Acad. Sci. USA 99 (2002) 8868-8873
27. Li X.F., Zanzonico P., Ling C.C., and O'Donoghue J. Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography. Technol. Cancer Res. Treat. 5 (2006) 147-155
28. Lin J., Lalani A.S., Harding T.C., Gonzalez M., Wu W.W., Luan B., Tu G.H., Koprivnikar K., VanRoey M.J., He Y., et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 65 (2005) 6901-6909
29. Makinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., Kauppinen R., Jackson D.G., Kubo H., Nishikawa S., et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7 (2001) 199-205
30. Makinen T., Veikkola T., Mustjoki S., Karpanen T., Catimel B., Nice E.C., Wise L., Mercer A., Kowalski H., Kerjaschki D., et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20 (2001) 4762-4773
31. Nathanson S.D. Insights into the mechanisms of lymph node metastasis. Cancer 98 (2003) 413-423
32. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296 (2002) 1883-1886
33. Pan Q., Chanthery Y., Liang W.C., Stawicki S., Mak J., Rathore N., Tong R.K., Kowalski J., Yee S.F., Pacheco G., et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11 (2007) 53-67
34. Soker S., Miao H.Q., Nomi M., Takashima S., and Klagsbrun M. VEGF mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF-receptor binding. J. Cell. Biochem. 85 (2002) 357-368
35. Stacker S.A., Achen M.G., Jussila L., Baldwin M.E., and Alitalo K. Lymphangiogenesis and cancer metastasis. Nat. Rev. Cancer 2 (2002) 573-583
36. Stacker S.A., Baldwin M.E., and Achen M.G. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 16 (2002) 922-934
37. Stracke M.L., and Liotta L.A. Multi-step cascade of tumor cell metastasis. In Vivo 6 (1992) 309-316
38. Wang L., Zeng H., Wang P., Soker S., and Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J. Biol. Chem. 278 (2003) 48848-48860
39. Yuan L., Moyon D., Pardanaud L., Breant C., Karkkainen M.J., Alitalo K., and Eichmann A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129 (2002) 4797-4806